Changes in Beneficial Ownership · 4
Definium Therapeutics, Inc.
DFTXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2626627-3_4seq1.xml
Filing details
- Report period
- 2026-09-25
- Issuer
- Definium Therapeutics, Inc.
- Issuer CIK
- 0001813814
- Trading symbol
- DFTX
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Wiley Matthew T.
- Reporting owner CIK
- 0001759703
- Relationship
- Officer
- Officer title
- Chief Commercial Officer
- Address
- C/O DEFINIUM THERAPEUTICS, INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Shares | 2026-09-25 | S · Form 4[F1] | 3,097 | D | 36.57[F2] | 359,036 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2025.↩ 1
- F2
- The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2026 at prices ranging from $36.24 to $36.98. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
Signature 1
- Signed
- /s/ Mark Sullivan, Attorney-in-Fact for Matthew T. Wiley
- Date
- 2026-09-29
Company context
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.